# Lysosomal Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/lysosomal-therapeutics

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.lysosomaltx.com
- Total disclosed funding: $31M
- Latest round: Series A (Jan 13, 2017)
- Investors on record: 8

## About

Lysosomal Therapeutics, Inc. focuses on developing innovative therapies for lysosomal storage disorders, offering specialized enzyme replacement and substrate reduction therapies to improve patient quality of life.Founded in 2014 in Cambridge, US, Lysosomal Therapeutics, Inc. specializes in therapies for lysosomal storage disorders. The company has successfully completed 4 deals, with its most recent funding round, a VENTURE DEBT, completed on October 25, 2019, raising USD 1.00 mn. The total amount raised by the company amounts to USD 16.13 mn. The current CEO is Kees Been.Lysosomal Therapeutics, Inc. specializes in the development of innovative therapies aimed at addressing lysosomal storage disorders (LSDs). Their core product offerings include enzyme replacement therapies and substrate reduction therapies designed to enhance the quality of life for individuals affected by these genetic conditions. These therapies function by replenishing deficient enzymes or reducing the accumulation of toxic substrates within lysosomes, ultimately aiming to alleviate the symptoms associated with LSDs. The company targets a diverse client base, including healthcare providers, hospitals, and specialty pharmacies, serving patients primarily in North America and select European markets. By focusing on the unmet needs of patients with LSDs, Lysosomal Therapeutics is committed to delivering effective solutions that improve patient outcomes and foster a better understanding of these rare diseases.The revenue model for Lysosomal Therapeutics is primarily structured around direct sales of its specialized therapeutic products to healthcare institutions and pharmacies. Transactions typically occur through negotiated contracts with hospitals and healthcare providers, ensuring a steady demand for their enzyme replacement therapies and substrate reduction therapies. Pricing plans are tailored to accommodate various healthcare systems, potentially involving tiered pricing based on volume or patient needs. The company’s flagship products are positioned to provide substantial value in the treatment of lysosomal storage disorders, reflecting the critical nature of these therapies in patient care. By establishing strong partnerships with healthcare providers, Lysosomal Therapeutics aims to create a sustainable revenue stream that supports ongoing research and development initiatives.Lysosomal Therapeutics plans to further develop and release new product lines targeting lysosomal storage disorders. The company aims to expand its market presence into additional regions in Europe by 2025. The recent VENTURE DEBT funding of USD 1.00 mn will be utilized to support these product developments and market expansion initiatives.

## Funding rounds

- Series A, Jan 13, 2017, $16M — Atlas Venture, Lilly Ventures, Hatteras Venture Partners, Roche Venture Fund, Sanofi Ventures, Mass General Brigham Ventures
- Series A, Feb 5, 2015, $10M — Atlas Venture, Lilly Ventures, Hatteras Venture Partners, Roche Venture Fund, Sanofi Ventures, Mass General Brigham Ventures, Orion Equity Partners
- Seed, Apr 30, 2014, $4.8M — Atlas Venture, Lilly Ventures, Hatteras Venture Partners, ORHEP, Roche Venture Fund, Sanofi Ventures, Mass General Brigham Ventures

## Investors

- Atlas Venture (https://capitalatlas.ai/funds/atlas-venture) — Seed, Series A
- Lilly Ventures (https://capitalatlas.ai/funds/lilly-ventures) — Seed, Series A
- Hatteras Venture Partners (https://capitalatlas.ai/funds/hatteras-venture-partners) — Seed, Series A
- ORHEP (https://capitalatlas.ai/funds/orhep) — Seed
- Roche Venture Fund (https://capitalatlas.ai/funds/roche-venture-fund) — Seed, Series A
- Sanofi Ventures (https://capitalatlas.ai/funds/sanofi-ventures) — Seed, Series A
- Mass General Brigham Ventures (https://capitalatlas.ai/funds/mass-general-brigham-ventures) — Seed, Series A
- Orion Equity Partners — Series A